News headlines about Surmodics (NASDAQ:SRDX) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Surmodics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.2933606366633 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of analysts have weighed in on SRDX shares. ValuEngine raised shares of Surmodics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub raised shares of Surmodics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research cut shares of Surmodics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Surmodics currently has an average rating of “Hold” and a consensus target price of $40.00.
Surmodics (NASDAQ:SRDX) traded down $0.85 during midday trading on Monday, hitting $32.35. 20,867 shares of the company’s stock were exchanged, compared to its average volume of 39,759. The company has a market capitalization of $434.88, a PE ratio of 65.10 and a beta of 0.83. Surmodics has a 12-month low of $21.90 and a 12-month high of $34.15.
Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Wednesday, November 8th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.19. Surmodics had a net margin of 5.37% and a return on equity of 6.18%. The company had revenue of $20.06 million for the quarter, compared to analysts’ expectations of $16.98 million. research analysts forecast that Surmodics will post -0.33 earnings per share for the current fiscal year.
In related news, VP Joseph J. Stich sold 1,000 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $27.28, for a total value of $27,280.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Surmodics (SRDX) Getting Somewhat Favorable Press Coverage, Report Shows” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-surmodics-srdx-stock-price.html.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.